Aphria Inc. (APHA)
(Delayed Data from NYSE)
$6.94 USD
-0.19 (-2.66%)
Updated May 3, 2019 04:02 PM ET
After-Market: $7.00 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.94 USD
-0.19 (-2.66%)
Updated May 3, 2019 04:02 PM ET
After-Market: $7.00 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter's (BAX) first-quarter earnings benefit from solid segmental performance and growth across all geographies.
LabCorp's (LH) Q1 Earnings Beat Estimates, Margins Down
by Urmimala Biswas
LabCorp's (LH) Covance Drug Development revenues improve despite COVID-19 hurdles.
Boston Scientific (BSX) Q1 Earnings Miss, Margins Decline
by Zacks Equity Research
The severity of the COVID-19 outbreak takes a toll on Boston Scientific's (BSX) global sales during the first quarter.
Chemed's (CHE) Q1 Earnings Beat Estimates, Margins Improve
by Zacks Equity Research
Chemed's (CHE) first-quarter 2020 results reflect strong segmental performances amid the coronavirus-led economic doldrums.
Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Contribution from Henry Schein's (HSIC) medical business in the form of point-of-care antibody rapid test is likely to have boosted Q1 performance amid the coronavirus pandemic.
What's in Store for IDEXX Laboratories (IDXX) in Q1 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) business is likely to have benefited from few cases in which pets were found to be COVID-19 positive globally.
Can IC and PI Arms Drive Boston Scientific (BSX) Q1 Earnings?
by Zacks Equity Research
Boston Scientific's (BSX) business trends in the first two months of the quarter in line with its expectations.
Illumina (ILMN) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Illumina (ILMN) is upbeat about its first-quarter sequencing consumable revenue growth.
ResMed (RMD) Q3 Earnings to Gain From Growing Ventilator Sales
by Zacks Equity Research
ResMed (RMD) is expected to have gained from increased adoption of flagship products and a ramped-up ventilator production capacity in Q3 amid the coronavirus pandemic.
Can Global Industrial Unit Drive Ecolab's (ECL) Q1 Earnings?
by Zacks Equity Research
Ecolab's (ECL) Global Industrial segment is likely to have gained from the Water, Food & Beverage and Life Sciences sub-units in the first quarter.
Cerner (CERN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Cerner's (CERN) first-quarter results are likely to reflect solid show by Population Health, Revenue Cycle and IT Works.
DexCom (DXCM) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
DexCom's (DXCM) first-quarter performance is likely to reflect rising global awareness of the company's real-time CGM.
Zacks.com featured highlights include: Ionis Pharmaceuticals, Aphria, Tabula Rasa Healthcare, InterDigital and Huron Consulting Group
by Zacks Equity Research
Zacks.com featured highlights include: Ionis Pharmaceuticals, Aphria, Tabula Rasa Healthcare, InterDigital and Huron Consulting Group
Align Technology (ALGN) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Align Technology (ALGN) is expected to have gained from continued adoption of Invisalign system in the first two months of Q1.
Can Diagnostics Aid Hologic (HOLX) Q2 Sales Amid Coronavirus?
by Zacks Equity Research
Strength in segmental businesses is likely to have aided Hologic's (HOLX) performance in second-quarter fiscal 2020 amid the coronavirus-led economic doldrums.
Will LabCorp's (LH) Coronavirus Test Boost Q1 Earnings?
by Zacks Equity Research
LabCorp (LH) is expected to have witnessed a significant fall in its quarterly revenues due to the coronavirus mayhem.
Aphria's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Aphria.
Grab 5 Top Stocks With Strong Earnings Beat Prospects
by Sanghamitra Saha
Invest in top-ranked stocks that are likely to beat their earnings estimates in the upcoming releases.
Can TAVR's SAPIEN 3 Aid Edwards Lifesciences (EW) Q1 Earnings?
by Zacks Equity Research
Robust customer adoption of the HemoSphere all-in-one monitoring platform and TAVR treatments is likely to have driven Edwards Lifesciences' (EW) Q1 revenues.
Company News for Apr 16, 2020
by Zacks Equity Research
Companies in the news are: PGR, APHA, WIT, LYTS
Will Brand Building Efforts Aid Aphria (APHA) in Q3 Earnings?
by Zacks Equity Research
Aphria's (APHA) focus on enhancing its brands and profitability is likely to have boosted its top line in third-quarter fiscal 2020.
Are Options Traders Betting on a Big Move in Aphria (APHA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Aphria (APHA) stock based on the movements in the options market lately.
Aphria Inc. (APHA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Aphria Inc. (APHA) closed at $2.89, marking a +1.05% move from the previous day.
Aphria Inc. (APHA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Aphria Inc. (APHA) closed at $2.54, marking a +1.2% move from the previous day.
Aphria Inc. (APHA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Aphria Inc. (APHA) closed at $2.16, marking a +0.47% move from the previous day.